CBUS Share Price Performance
US$1.70
-0.66 (-27.97%)
88.2% undervalued intrinsic discount
US$14.40
Fair Value
Price US$1.70
AnalystConsensusTarget US$14.40
AnalystHighTarget US$25.00
AnalystLowTarget US$1.60
Fair ValueUS$14.40
Share Pricen/a
Cibus, Inc. Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 4 Fair Values set on narratives written by author
CBUS Community Narratives
AN
Fair Value US$14.4 88.2% undervalued intrinsic discount
Accelerating EU Gene Editing Acceptance Will Open Global Markets
0users have liked this narrative
0users have commented on this narrative
4users have followed this narrative
AN
Fair Value US$25 93.2% undervalued intrinsic discount
Population Growth And Climate Trends Will Drive Gene-edited Crop Adoption
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
Fair Value US$1.6 6.3% overvalued intrinsic discount
Regulatory Risks And Concentration Will Delay Expansion But Allow Turnaround
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
Population Growth And Climate Trends Will Drive Gene-edited Crop Adoption
Key Takeaways Cibus's advanced gene-editing platform and strong regulatory status position it to rapidly capture high-margin royalty and licensing income in expanding global markets. Partner-funded development and a lean operating model reduce cash burn, accelerating breakeven and enabling stronger, earlier earnings growth as new revenue streams ramp up.Read more
6
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
US$25
93.2% undervalued intrinsic discount
AnalystHighTarget's Fair Value
Revenue
234.35% p.a.
Profit Margin
9.34%
Future PE
137.28x
Price in 2028
US$20.12
Accelerating EU Gene Editing Acceptance Will Open Global Markets
Key Takeaways Accelerating regulatory acceptance and efficient technology platform will expand market opportunities, boost revenue growth, and improve margins through rapid speed-to-market. Diversified royalty partnerships and disciplined cost management are expected to enhance earnings stability, cash flow, and recurring revenue streams.Read more
24
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
4users have followed this narrative
AN
US$14.4
88.2% undervalued intrinsic discount
AnalystConsensusTarget's Fair Value
Revenue
185.54% p.a.
Profit Margin
16.06%
Future PE
74.13x
Price in 2028
US$11.64
Regulatory Risks And Concentration Will Delay Expansion But Allow Turnaround
Key Takeaways Dependency on a few product launches and regulatory delays risks volatile revenue growth and postponed entry into key markets. High R&D costs and reliance on external partnerships threaten profitability, with scalability and recurring royalties remaining critical uncertainties.Read more
10
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
US$1.6
6.3% overvalued intrinsic discount
AnalystLowTarget's Fair Value
Revenue
41.32% p.a.
Profit Margin
16.25%
Future PE
67.15x
Price in 2028
US$1.29
Trending Discussion
Recently Updated Narratives
AN
Accelerating EU Gene Editing Acceptance Will Open Global Markets
Fair Value: US$14.4 88.2% undervalued intrinsic discount
4 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Regulatory Risks And Concentration Will Delay Expansion But Allow Turnaround
Fair Value: US$1.6 6.3% overvalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Population Growth And Climate Trends Will Drive Gene-edited Crop Adoption
Fair Value: US$25 93.2% undervalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Cibus, Inc. Key Details
Last Reported Earnings
Sep 30, 2025
Next Reporting Earnings
n/a
- -2.26
- 100.00%
- -3,133.92%
- 434.9%
About CBUS
- Founded
- 2001
- Employees
- 158
- CEO
- WebsiteView website
Cibus, Inc., an agricultural biotechnology company, develops and licenses gene edited plant traits using gene editing technologies to enhance farming productivity or produce renewable low carbon plant products. It focuses on trait productivity in the productivity traits that enable farmers to have higher yields and reduce the use of the crop protection chemicals and fertilizers; and sustainable ingredients, which enable corporations to replace ingredients that are fossil fuel based or whose production results in increased greenhouse gases. The company was formerly known as Calyxt, Inc. and changed its name to Cibus, Inc. in June 2023. Cibus, Inc. was founded in 2001 and is headquartered in San Diego, California.
